MARKET

SERA

SERA

Sera Prognostics, Inc.
NASDAQ
1.800
0.000
0.00%
After Hours: 1.800 0 0.00% 16:10 06/26 EDT
OPEN
1.780
PREV CLOSE
1.800
HIGH
1.810
LOW
1.740
VOLUME
46.31K
TURNOVER
--
52 WEEK HIGH
4.090
52 WEEK LOW
1.560
MARKET CAP
70.49M
P/E (TTM)
-2.7842
1D
5D
1M
3M
1Y
5Y
1D
Sera Prognostics part of ARPA-H award for birth safety test development
TipRanks · 2d ago
Sera Prognostics To Participate In A Multi-institutional Research Program That Was Awarded Up To $10.4M By The Advanced Research Projects Agency For Health To Develop A Novel Point-of-care Diagnostic Test Designed To Improve The Safety Of Labor And Delivery
Benzinga · 2d ago
Sera Prognostics joins ARPA-H award worth up to $10.4 million for point-of-care birth diagnostic
PUBT · 2d ago
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
PR Newswire · 2d ago
Sera Prognostics welcomes Illinois move to expand Medicaid coverage for preterm birth blood test
PUBT · 3d ago
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
PR Newswire · 3d ago
Weekly Report: what happened at SERA last week (0615-0619)?
Weekly Report · 5d ago
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy
NASDAQ · 06/19 16:00
More
About SERA
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Webull offers Sera Prognostics Inc stock information, including NASDAQ: SERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SERA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SERA stock methods without spending real money on the virtual paper trading platform.